Lexicon Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LEXICON PHARMS INC
LEXICON PHARMS INC has one approved drug.
There are three US patents protecting LEXICON PHARMS INC drugs.
Summary for Lexicon Pharms Inc
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Lexicon Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | 7,781,577 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 8,217,156 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 7,781,577 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | 8,476,413 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 8,476,413 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Lexicon Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Peru | 20100260 | ⤷ Start Trial |
| South Africa | 201100175 | ⤷ Start Trial |
| Poland | 2332947 | ⤷ Start Trial |
| Singapore | 185317 | ⤷ Start Trial |
| Austria | E496888 | ⤷ Start Trial |
| South Africa | 200902231 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lexicon Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2089361 | CA 2019 00042 | Denmark | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1363 20190430 |
| 2089361 | 1990043-0 | Sweden | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1363 20190430 |
| 2089361 | 2019/044 | Ireland | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/19/1363 20190430 |
| 2089361 | SPC/GB19/054 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/19/1363 (NI) 20190430; UK PLGB 53567/0001 20190430 |
| 2089361 | 132019000000113 | Italy | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZYNQUISTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1363, 20190430 |
| 2089361 | CR 2019 00042 | Denmark | ⤷ Start Trial | PRODUCT NAME: SOTAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1363 20190430 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
